Display options
Cite
Li LM, Wang D, Zen K. MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol. 2014;2(3):162-9doi: 10.14218/JCTH.2014.00015.
Li, L. M., Wang, D., & Zen, K. (2014). MicroRNAs in Drug-induced Liver Injury. Journal of clinical and translational hepatology, 2(3), 162-9. https://doi.org/10.14218/JCTH.2014.00015
Li, Li-Min, et al. "MicroRNAs in Drug-induced Liver Injury." Journal of clinical and translational hepatology vol. 2,3 (2014): 162-9. doi: https://doi.org/10.14218/JCTH.2014.00015
Li LM, Wang D, Zen K. MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol. 2014 Sep;2(3):162-9. doi: 10.14218/JCTH.2014.00015. Epub 2014 Sep 15. PMID: 26357624; PMCID: PMC4521241.
Copy Download .nbib Format: NLM
Share it on

J Clin Transl Hepatol. 2014 Sep;2(3):162-9. doi: 10.14218/JCTH.2014.00015. Epub 2014 Sep 15.

MicroRNAs in Drug-induced Liver Injury.

Journal of clinical and translational hepatology

Li-Min Li, Dong Wang, Ke Zen

Affiliations

  1. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.

PMID: 26357624 PMCID: PMC4521241 DOI: 10.14218/JCTH.2014.00015

Abstract

Drug-induced liver injury (DILI) is a leading cause of acute liver failure, and a major reason for the recall of marketed drugs. Detection of potential liver injury is a challenge for clinical management and preclinical drug safety studies, as well as a great obstacle to the development of new, effective and safe drugs. Currently, serum levels of alanine and aspartate aminotransferases are the gold standard for evaluating liver injury. However, these levels are assessed by nonspecific, insensitive, and non-predictive tests, and often result in false-positive results. Therefore, there is an urgent need for better DILI biomarkers to guide risk assessment and patient management. The discovery of microRNAs (miRNAs) as a new class of gene expression regulators has triggered an explosion of research, particularly on the measurement of miRNAs in various body fluids as biomarkers for many human diseases. The properties of miRNA-based biomarkers, such as tissue specificity and high stability and sensitivity, suggest they could be used as novel, minimally invasive and stable DILI biomarkers. In the current review, we summarize recent progress concerning the role of miRNAs in diagnosing and monitoring both clinical and preclinical DILI, and discuss the main advantages and challenges of miRNAs as novel DILI biomarkers.

Keywords: Biomarker; Diagnosis; Drug-induced liver injury (DILI); MicroRNA

References

  1. PLoS One. 2012;7(5):e37395 - PubMed
  2. Braz J Infect Dis. 2004 Apr;8(2):156-63 - PubMed
  3. J Clin Gastroenterol. 2010 Jul;44(6):e128-32 - PubMed
  4. Annu Rev Pharmacol Toxicol. 2007;47:513-39 - PubMed
  5. Toxicol Sci. 2011 Aug;122(2):457-65 - PubMed
  6. Toxicology. 2008 Mar 20;245(3):194-205 - PubMed
  7. Chem Biol Interact. 2004 Nov 1;150(1):35-51 - PubMed
  8. Mol Med Rep. 2012 Jul;6(1):75-82 - PubMed
  9. Semin Liver Dis. 2009 Nov;29(4):383-92 - PubMed
  10. Int J Oncol. 2012 Nov;41(5):1871-8 - PubMed
  11. Curr Hepat Rep. 2013 Mar 1;12(1):53-58 - PubMed
  12. Eur J Gastroenterol Hepatol. 2013 Jul;25(7):825-9 - PubMed
  13. Drug Metab Dispos. 2009 Dec;37(12 ):2383-92 - PubMed
  14. Gastroenterology. 2011 Jul;141(1):338-47 - PubMed
  15. Toxicol Pathol. 2005;33(1):146-54 - PubMed
  16. Expert Rev Gastroenterol Hepatol. 2010 Apr;4(2):225-34 - PubMed
  17. Eur J Clin Pharmacol. 2008 Oct;64(10):999-1004 - PubMed
  18. Hepatology. 2008 Aug;48(2):588-96 - PubMed
  19. PLoS One. 2012;7(5):e36323 - PubMed
  20. Sci Transl Med. 2012 Sep 19;4(152):152ra129 - PubMed
  21. Mol Pharmacol. 2009 Oct;76(4):702-9 - PubMed
  22. Antimicrob Agents Chemother. 2010 Jul;54(7):2847-54 - PubMed
  23. Hepatology. 2005 Feb;41(2):380-2 - PubMed
  24. Toxicol Sci. 2011 Sep;123(1):1-14 - PubMed
  25. Pharmacogenomics. 2010 May;11(5):607-11 - PubMed
  26. Curr Drug Metab. 2008 Jul;9(6):538-45 - PubMed
  27. Med Res Rev. 2012 Mar;32(2):326-48 - PubMed
  28. J Toxicol Sci. 2007 Oct;32(4):401-9 - PubMed
  29. Liver Int. 2014 Mar;34(3):367-78 - PubMed
  30. Cell Res. 2008 Oct;18(10):997-1006 - PubMed
  31. J Clin Rheumatol. 2008 Dec;14(6):363-4 - PubMed
  32. Clin Pharmacol Ther. 2011 Jun;89(6):788-90 - PubMed
  33. Clin Liver Dis. 2007 Aug;11(3):477-505, v - PubMed
  34. Annu Rev Pharmacol Toxicol. 2013;53:377-400 - PubMed
  35. Am J Trop Med Hyg. 1992 Sep;47(3):265-70 - PubMed
  36. Cell. 2003 Jun 13;113(6):673-6 - PubMed
  37. Nature. 2004 Sep 16;431(7006):350-5 - PubMed
  38. PLoS One. 2012;7(11):e49524 - PubMed
  39. Curr Med Chem. 2009;16(23 ):3041-53 - PubMed
  40. Clin Liver Dis. 2007 Aug;11(3):525-48, vi - PubMed
  41. Drug Discov Today. 2011 Aug;16(15-16):697-703 - PubMed
  42. Clin Chem. 2010 Dec;56(12 ):1830-8 - PubMed
  43. Am J Health Syst Pharm. 1999 Jun 1;56(11):1081-91; quiz 1091-3 - PubMed
  44. Cancer Res. 2006 Sep 15;66(18):9090-8 - PubMed
  45. Curr Opin Gastroenterol. 2012 May;28(3):198-202 - PubMed
  46. World J Gastroenterol. 2009 Jun 21;15(23 ):2817-33 - PubMed
  47. Hepatology. 2013 Aug;58(2):777-87 - PubMed
  48. Gastroenterology. 2010 Jun;138(7):2246-59 - PubMed
  49. Drug Discov Today. 2003 Sep 15;8(18):832-7 - PubMed
  50. Br J Pharmacol. 2007 Mar;150(6):808-15 - PubMed
  51. Hepatology. 2010 Dec;52(6):2065-76 - PubMed
  52. World J Gastroenterol. 2012 Jun 14;18(22):2798-804 - PubMed
  53. Cell. 1993 Dec 3;75(5):843-54 - PubMed
  54. Hepatology. 2010 Mar;51(3):1007-16 - PubMed
  55. Gut. 2009 Oct;58(10):1375-81 - PubMed
  56. Hepatology. 2012 Nov;56(5):1946-57 - PubMed
  57. Bioanalysis. 2012 Sep;4(18):2204 - PubMed
  58. Nat Genet. 2009 Jul;41(7):816-9 - PubMed
  59. J Appl Toxicol. 2013 Nov;33(11):1330-6 - PubMed
  60. Hepatology. 2006 Dec;44(6):1581-8 - PubMed
  61. PLoS One. 2008 Sep 05;3(9):e3148 - PubMed
  62. Br J Haematol. 2008 May;141(5):672-5 - PubMed
  63. Cell. 2004 Jan 23;116(2):281-97 - PubMed
  64. Biochem Pharmacol. 2004 Dec 1;68(11):2249-61 - PubMed
  65. Nature. 2005 Dec 1;438(7068):685-9 - PubMed
  66. Arch Biochem Biophys. 2007 Oct 1;466(1):66-77 - PubMed
  67. Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4 - PubMed
  68. Toxicol Appl Pharmacol. 2009 Jun 15;237(3):317-30 - PubMed
  69. Hepatology. 2010 Feb;51(2):615-20 - PubMed
  70. PLoS One. 2012;7(2):e30250 - PubMed
  71. Clin Chem. 2010 Nov;56(11):1733-41 - PubMed
  72. World J Gastroenterol. 2008 Nov 28;14 (44):6774-85 - PubMed
  73. Mutat Res. 2007 Jun 1;619(1-2):30-7 - PubMed
  74. Chem Res Toxicol. 2012 Jan 13;25(1):83-93 - PubMed
  75. Clin J Am Soc Nephrol. 2012 Sep;7(9):1528-33 - PubMed
  76. Toxicol Sci. 2012 Feb;125(2):335-44 - PubMed
  77. Toxicol Lett. 2010 Feb 15;192(3):387-94 - PubMed
  78. Nat Genet. 2010 Aug;42(8):711-4 - PubMed
  79. Science. 2005 Sep 2;309(5740):1577-81 - PubMed
  80. Hepatology. 2006 Mar;43(3):618-31 - PubMed
  81. Cell Metab. 2006 Feb;3(2):87-98 - PubMed
  82. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):320-8 - PubMed
  83. Toxicol Pathol. 2013 Jul;41(5):795-804 - PubMed
  84. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7 - PubMed
  85. World J Gastroenterol. 2012 Nov 7;18(41):5972-8 - PubMed
  86. Cell. 2009 Jan 23;136(2):215-33 - PubMed
  87. Toxicology. 2014 May 7;319:75-84 - PubMed
  88. J Toxicol Sci. 2009 Jun;34(3):281-93 - PubMed
  89. Mol Med Rep. 2012 Jun;5(6):1428-32 - PubMed
  90. Hepatology. 2011 Nov;54(5):1767-76 - PubMed
  91. Int J Nanomedicine. 2012;7:5859-72 - PubMed
  92. Mayo Clin Proc. 2014 Jan;89(1):95-106 - PubMed
  93. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  94. Toxicol Pathol. 2005;33(1):1-5 - PubMed
  95. Biomark Med. 2013 Apr;7(2):307-15 - PubMed
  96. US Gastroenterol Hepatol Rev. 2010 Jan 1;6:73-80 - PubMed
  97. Nat Rev Drug Discov. 2005 Jun;4(6):489-99 - PubMed
  98. Annu Rev Med. 2009;60:167-79 - PubMed

Publication Types